SCHEMBL10276524

SCHEMBL10276524

COc1ccc(C(=O)NC[C@](O)(C(N)=O)N2CCN(S(C)(=O)=O)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 3/20 0.55
TP53 P04637 2/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 1/20 0.46
POLB P06746 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 3/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
DPP4 P27487 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
USP5 P45974 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10277104 0.86 ADAM17 (0.59) ADAM17ALDH1A1MAPT
SCHEMBL1504573 0.84 ADAM17 (0.60) ADAM17ALDH1A1MAPT
SCHEMBL10276692 0.83 ADAM17 (0.61) ADAM17ALDH1A1LMNA
SCHEMBL10276029 0.83 ADAM17 (0.61) ADAM17KMT2APOLBALDH1A1LMNA
SCHEMBL10276816 0.81 ADAM17 (0.51) ADAM17KMT2ACA2
SCHEMBL10276521 0.79 ADAM17 (0.64) ADAM17
SCHEMBL10276279 0.79 ADAM17 (0.65) ADAM17ALDH1A1
SCHEMBL1504939 0.76 ADAM17 (0.60) ADAM17TP53THRBKMT2APOLB
SCHEMBL1504806 0.72 ADAM17 (0.80) ADAM17TP53KMT2APOLBALDH1A1
SCHEMBL10476143 0.72 ADAM17 (0.70) ADAM17TP53KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477968-B1 N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS GALDERMA RES & DEV (FR) 2013-10-23 EP disclosed
US-20120178934-A1 N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178934-A1 N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS CTSB, TPSAB1, PIGS ADAM17 6/4885TP53 637/4885THRB 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.